VCNX Share Price | Vaccinex, Inc. Stock Analysis & Recommendation

Q: How big is Vaccinex, Inc.?

Market Cap: As of Jun 18, Vaccinex, Inc. has a market capitalization of 1.90 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Vaccinex, Inc. reported net sales of 0.59 million and a net profit of -18.63 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds of -2.49 million and total assets amounting to 2.60 million.

Q: What does Vaccinex, Inc. do?

Overview:Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics, focused on serious diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024) Most recent Net Profit: -3 Million (Quarterly Results - Dec 2024) Market-cap: USD 1.90 Million (Micro Cap) Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.43 Return on Equity: 797.03% Price to Book: -0.77 Contact Details:Address: 1895 Mount Hope Ave, ROCHESTER NY: 14620-4540 Tel: 1 585 2712700 Fax: 1 585 2712765 Website: http://www.vaccinex.com/

Q: Is Vaccinex, Inc. overvalued or undervalued?

As of 8 November 2021, the valuation grade for Vaccinex, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative financial ratios, including a price-to-book value of -0.92 and an EV to EBITDA of -0.07, which suggest that the company is not generating positive returns or value for shareholders. In comparison to its peers, Vaccinex's EV to EBIT ratio of -0.06 stands in stark contrast to Champions Oncology, Inc., which has a P/E ratio of 17.32, highlighting the disparity in financial health and market perception. Other peers, such as C4 Therapeutics, Inc., are also in a risky category with a P/E of -1.02, but they still reflect a better valuation outlook than Vaccinex. The company's significant underperformance is further illustrated by its one-year stock return of -87.21% compared to a 10.26% return for the S&P 500, reinforcing the notion that it is overvalued in its current state.

Q: Is Vaccinex, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Vaccinex, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include bearish moving averages on the daily timeframe, a bearish KST on both weekly and monthly timeframes, and mildly bearish signals from Bollinger Bands. The MACD shows mildly bullish signals on the weekly and monthly, but this is overshadowed by the overall bearish trend. In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a 1-year return of -86.43% versus the S&P 500's 17.14%, and a staggering -99.94% over the past 5 and 10 years.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.8 k

Shareholding (Dec 2024)

FII

0.04%

Held by 5 FIIs

DII

99.68%

Held by 0 DIIs

Promoter

0.00%

How big is Vaccinex, Inc.?

22-Jun-2025

As of Jun 18, Vaccinex, Inc. has a market capitalization of 1.90 million, with net sales of 0.59 million and a net profit of -18.63 million over the last four quarters. The company has shareholder's funds of -2.49 million and total assets of 2.60 million as of Dec 24.

View full answer

What does Vaccinex, Inc. do?

22-Jun-2025

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics for serious diseases. As of December 2024, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $1.90 million.

View full answer

Is Vaccinex, Inc. overvalued or undervalued?

25-Jun-2025

As of November 8, 2021, Vaccinex, Inc. is considered overvalued with negative financial ratios and a significant stock return decline of -87.21%, indicating a deterioration in its financial standing compared to peers like Champions Oncology, Inc. and C4 Therapeutics, Inc.

View full answer

Is Vaccinex, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Vaccinex, Inc. is in a bearish trend with weak strength, indicated by bearish moving averages and KST, underperforming the S&P 500 with a 1-year return of -86.43%.

View full answer

Compare Vaccinex, Inc. with Similar Stocks

BioXcel Therapeutics, Inc.Athira Pharma, Inc.NanoString Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.43

Return on Equity

797.03%

Price to Book

-1.42

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2024)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

42.86%

6 Months

-69.92%

1 Year

-82.86%

2 Years

-98.76%

3 Years

-99.55%

4 Years

-99.78%

5 Years

-99.84%

Vaccinex, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

1.55%

EBIT Growth (5y)

7.19%

EBIT to Interest (avg)

-21.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.43

Sales to Capital Employed (avg)

-0.16

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.06%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.92

EV to EBIT

-0.06

EV to EBITDA

-0.07

EV to Capital Employed

-0.34

EV to Sales

1.21

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (0.28%)

Foreign Institutions

Held by 5 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 100.00% vs -50.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 40.35% vs -1.79% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-4.50",
          "chgp": "24.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-5.70",
          "chgp": "40.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,901.40%",
          "val2": "-87,538.50%",
          "chgp": "7,163.71%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.37% vs -2.53% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.60",
          "val2": "-22.80",
          "chgp": "18.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "2.10",
          "chgp": "-42.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.60",
          "val2": "-20.30",
          "chgp": "8.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-31,173.00%",
          "val2": "-40,149.10%",
          "chgp": "897.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Dec'24

Sep'24

Change(%)

Net Sales

0.20

0.10

100.00%

Operating Profit (PBDIT) excl Other Income

-3.40

-4.50

24.44%

Interest

0.00

Exceptional Items

-0.00

-0.10

100.00%

Consolidate Net Profit

-3.40

-5.70

40.35%

Operating Profit Margin (Excl OI)

-15,901.40%

-87,538.50%

7,163.71%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2024 is 100.00% vs -50.00% in Sep 2024

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is 40.35% vs -1.79% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.60

Operating Profit (PBDIT) excl Other Income

-18.60

-22.80

18.42%

Interest

0.00

0.40

-100.00%

Exceptional Items

1.20

2.10

-42.86%

Consolidate Net Profit

-18.60

-20.30

8.37%

Operating Profit Margin (Excl OI)

-31,173.00%

-40,149.10%

897.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.37% vs -2.53% in Dec 2023

All Annual Results

Company CV

About Vaccinex, Inc.

Vaccinex, Inc.

Pharmaceuticals & Biotechnology

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.

Company Coordinates

Company Details

1895 Mount Hope Ave , ROCHESTER NY : 14620-4540

Tel: 1 585 2712700

http://www.vaccinex.com/

Registrar Details

Vaccinex, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Vaccinex, Inc.?

Watch in Real-Time

What does Vaccinex, Inc. do?

Is Vaccinex, Inc. overvalued or undervalued?

Is Vaccinex, Inc. technically bullish or bearish?

Compare Vaccinex, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Vaccinex, Inc.

Company Coordinates